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This study is the first report of the solubilization of sorafenib (SFB), a water insoluble drug, by polyam-
idoamine (PAMAM) dendrimers and -cyclodextrin ( -CD). For this study whole generations (G4 and G5) 
of PAMAM dendrimers have been used. The aqueous solubility of sorafenib was measured in the presence 
of dendrimers and -cyclodextin  at 30 ◦ C at pH 4, 7.4, and 10 using the Higuchi rotating bottle method. 
The amount of solubilized SFB was measured by HPLC-UV method. FTIR and UV-Vis spectroscopy were 
used to confirm complexation. From the phase solubility studies, it was found that PAMAM dendrimers in-
creased SFB solubility most in pH 4. The maximum solubilizing effect was for G4 PAMAM dendrimers at 
pH 4 up to 36 folds. -CD did not or slightly increased the solubility of SFB. 
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1. INTRODUCTION 
 
Sorafenib (SFB) is a practically insoluble, orally 
administered multikinase inhibitor that prevents tu-
mor growth by anti-angiogenic, antiproliferative and/or 
pro-apoptotic effects [1]. Sorafenib first was approved 
by the U.S. Food and Drug Administration (FDA) for 
advanced renal cell carcinoma in December 2005. 2 
years later the drug became FDA approved for hepato-
cellular carcinoma in November 2007. However, there 
is a major problem associated with the preparation of 
successful sorafenib formulations, this drug is practi-
cally insoluble in water. A commonly used technique to 
increase the solubility of poorly water soluble drugs is 
by supramolecular complexation [2]. 
Dendrimers, due to their well defined structure, 
compact globular shape, size, monodispersity and con-
trollable surface functional groups, have gained much 
attention as carriers for drug delivery and solubilisa-
tion of poorly soluble drugs [3, 4]. The interactions that 
lead to an increase in solubility include physical en-
trapment of the drug molecules inside the dendrimer 
structure or the drug being attached onto the den-
drimer surface to prepare dendrimer-drug conjugates 
[2]. The PEG coating on the periphery of the amine-
terminated whole generation dendrimers chemically 
can increase drug loading and overcome few drawbacks 
of drug-loaded dendrimeric system like hemolytic tox-
icity, drug leakage, macrophageal uptake and etc [5]. 
Among the macromolecules used to solubilize drugs 
the cyclodextrins are the most widely used. Natural 
cyclodextrins (CDs) are cyclic oligosaccharides made up 
of six ( -CD), seven ( -CD) and eight ( -CD) d-
glucopyranose units linked by α-1,4-glycosidic bonds. 
The molecular structure of these glucose derivatives 
generates a hydrophilic exterior surface and a cylinder-
shaped electron-rich internal hydrophobic cavity. The 
lipophilic cavity enables CDs to form non-covalent in-
clusion complexes with a wide variety of appropriately 
sized poorly water-soluble compounds in aqueous solu-
tions. These complexes have been extensively studied 
for the solubilization of poorly soluble drugs because 
they offer a variety of physicochemical advantages, 
including the possibility for increased water solubility, 
chemical stability, bioavailability and clinical activity. 
However, due to various reasons such as their high 
molecular weight, relatively low water solubility and 
possible parenteral toxicity, cost and dosage, the 
amount of CD that can be used in most pharmaceutical 
formulations is limited [2]. 
In this study, we aimed to study SFB solubility in 
the presence of uncoated and stealth amine terminated 
full generation EDA core PAMAM dendrimers (G4 and 
G5) in aqueous solutions at pH 4, 7.4, 10 in comparison 
with -cyclodextrin. 
 
2. MATERIALS AND METHODS 
 
2.1 Materials 
 
Sorefenib tosylate (99.6% purity) was purchased 
from Hangzhou Hetd Industry Company (Hangzhou, 
Zhejiang, China). It is off-white or yellowish crystalline 
powder. It is very poorly soluble in water; maximum 
solubility in plain water is estimated to be about 10-
20 M. It is soluble in DMSO at 200 mg/ml and very 
poorly soluble in ethanol. (27) Ethylenediamine core 
PAMAM dendrimers were obtained from Sigma-Aldrich 
Chemical Company. Activated PEG-NHS was supplied 
from Jenkem (USA). -CD  was gifted by Dr. Hashem 
Montaseri. Potassium dihydrogen phosphate, Dipotas-
sium hydrogen phosphate, sodium bicarbonate, tris and 
methanol were purchased from Merck Company, and 
Acetonitrile (HPLC grade) was obtained from Caledon 
(Canada). 
 
2.2 HPLC Analysis of Sorafenib 
 
SFB was analyzed by high performance liquid 
chromatography. Chromatographic analysis was per-
formed using a Knauer separations system (Germany) 
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with P1000 pump, equipped with a multiple wave-
length UV detector (UV 2600 detector) set at a wave-
length of max 265 nm. Separation of the analytes from 
potentially interfering material was achieved at ambi-
ent temperature using C18 column (Knauer Eurospher 
150 mm×4.6 mm with precolumn). The mobile phase 
used for the chromatographic separation was composed 
of acetonitrile (25 mM) : potassium phosphate (pH 7.4) 
(55:45, v/v), and was delivered isocratically at a ﬂow 
rate of 1.5ml/min; injection volume 50 L; retention 
time 4.7 min.  
This analysis method was validated. Linearity, 
specificity, accuracy and precision were determined. 
 
2.3 PEGylation of Dendrimer 
 
PEG–PAMAM conjugates at different degree of 
PEGylation were synthesized by reacting the primary 
amino groups of PAMAM dendrimers with the NHS–
mPEG (PEG, Mw  5000) in 25 mM phosphate buffer 
(pH 8.0), with molar ratios of 2:1, 4:1, 8:1 and 16:1 
between PEG and PAMAM dendrimer. The reaction 
mixtures were stirred at 25 °C for 4 h in dark. The 
degree of PEGylation was monitored by fluorescamine 
and confirmed by 1 H-NMR. The resulting conjugate, 
PAMAM-PEG, was purified by Amicon centrifugal 
filter units and PEG removal was confirmed by size 
exclusion chromatography. 
 
2.4 Preparation of SFB: β-CD, Uncoated and 
Stealth PAMAM Dendrimer Complexes 
 
To prepare complexes of SFB and -CD, classic or 
stealth PAMAM dendrimers, an excess amount of SFB 
tosylate was added. The reaction mixture was stirred at 
30 C in the dark for 24 h. Then samples were centri-
fuged at 10,000g for 15 min. Aliquots of the supernatants 
were analyzed by validated high performance liquid 
chromatography (HPLC) method. The effect of pH on the 
solubility of SFB in an aqueous solutions of -CD, classic 
and stealth PAMAM dendrimers solution was studied 
using Na-acetate buffer (pH  4), phosphate buffer 
(pH  7.4) and Na-bicarbonate buffer (pH  10). Phase 
solubility diagrams were constructed by plotting the 
molar concentrations of SFB (solubility) versus molar 
concentrations of -CD and dendrimers. Mathematical 
analysis of these diagrams, provided estimates of the 
apparent equilibrium stability constants. 
 
3. RESULTS AND DISCUSSION 
 
The percent of PAMAM primary amines PEGylation 
was determined with fluorescamine assay depending on 
different ratios of PAMAM whole generation den-
drimers/PEG and time. It was seemed that more than 
1:16 ratio (G4.0: PEG) there was a plateau in percent of 
PEGylation and it was not increased. Also it has been 
shown that 4 hours is enough for reaction completion. 
The percent of PEGylation was decreased with longer 
time. An example of the data has been shown in Fig. 1. 
PEGylation was also confirmed by the appearance 
of signals at 3.2 ppm and 3.4–3.6 ppm in 1 H-NMR 
spectra of the conjugates, which correspond to the pro-
tons of CH2CH2O repeating unit and terminal OCH3 
groups of PEG, respectively. PEGylation degree was 
estimated using the proton integration method, by 
taking the characteristic peaks of PEG and PAMAM 
dendrimer into account. 
 
 
 
Fig. 1 – PEGylation data for different molar ratio 
 
The solubility of sorafenib ranged from 0.96 to 
2.9 mcg/mL between pH 4-10. Unlike -CD, PAMAM 
dendrimers (G4.0 and G5.0) increased the solubility of 
SFB significantly at three pHs in a range of 2-36 folds. 
Dendrimers were found to have higher complexation 
efficiency (product of intrinsic molar solubility of SFB 
and stability constants for SFB–dendrimer complexes) 
at pH 4. The difference in loading amount can be ex-
plained by conformation of PAMAM dendrimer branch-
es at various pHs (Figure 2-4). 
 
 
 
Fig. 2 – Phase solubility diagram of SFB in the presence of 
G4.0 and G5.0 PAMAM dendrimer and -CD at pH 4  
 
 
 
Fig. 3 – Phase solubility diagram of SFB in the presence of 
G4.0 and G5.0 PAMAM dendrimer at pH 4 
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Fig. 4 – Phase solubility diagram of SFB in the presence of G4.0 and PEG-G4.0 at pH 4 
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